FCCC LOGO Faculty Publications
Spiess PE , Agarwal N , Bangs R , Boorjian SA , Buyyounouski MK , Clark PE , Downs TM , Efstathiou JA , Flaig TW , Friedlander T , Greenberg RE , Guru KA , Hahn N , Herr HW , Hoimes C , Inman BA , Jimbo M , Kader AK , Lele SM , Meeks JJ , Michalski J , Montgomery JS , Pagliaro LC , Pal SK , Patterson A , Plimack ER , Pohar KS , Porter MP , Preston MA , Sexton WJ , Siefker-Radtke AO , Sonpavde G , Tward J , Wile G , Dwyer MA , Gurski LA
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2017 Oct;15(10) :1240-1267
Back to previous list
Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
Notes
Spiess, Philippe E Agarwal, Neeraj Bangs, Rick Boorjian, Stephen A Buyyounouski, Mark K Clark, Peter E Downs, Tracy M Efstathiou, Jason A Flaig, Thomas W Friedlander, Terence Greenberg, Richard E Guru, Khurshid A Hahn, Noah Herr, Harry W Hoimes, Christopher Inman, Brant A Jimbo, Masahito Kader, A Karim Lele, Subodh M Meeks, Joshua J Michalski, Jeff Montgomery, Jeffrey S Pagliaro, Lance C Pal, Sumanta K Patterson, Anthony Plimack, Elizabeth R Pohar, Kamal S Porter, Michael P Preston, Mark A Sexton, Wade J Siefker-Radtke, Arlene O Sonpavde, Guru Tward, Jonathan Wile, Geoffrey Dwyer, Mary A Gurski, Lisa A eng Practice Guideline J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.